MedPath

JANSSEN PHARMACEUTICAL K.K.

๐Ÿ‡ฏ๐Ÿ‡ตJapan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

349

Active:44
Completed:206

Trial Phases

5 Phases

Phase 1:62
Phase 2:66
Phase 3:70
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (246 trials with phase data)โ€ข Click on a phase to view related trials

Phase 3
70 (28.5%)
Phase 2
66 (26.8%)
Phase 1
62 (25.2%)
Not Applicable
36 (14.6%)
Phase 4
7 (2.8%)
phase_2_3
4 (1.6%)
phase_1_2
1 (0.4%)

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3
Active, not recruiting
Conditions
Erythrodermic Psoriasis
Generalized Pustular Psoriasis
Interventions
First Posted Date
2024-03-06
Last Posted Date
2025-07-18
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
19
Registration Number
NCT06295692
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

JR Sapporo Hospital, Hokkaido, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Ichinomiya Municipal Hospital, Ichinomiya, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Teikyo University Hospital, Itabashi Ku, Japan

and more 9 locations

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Phase 3
Recruiting
Conditions
X-Linked Retinitis Pigmentosa
First Posted Date
2023-07-03
Last Posted Date
2025-07-18
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
4
Registration Number
NCT05926583
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

National Hospital Organization Tokyo Medical Center, Meguro-ku, Japan

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Phase 1
Active, not recruiting
Conditions
Urinary Bladder Neoplasms
Receptors, Fibroblast Growth Factor
Interventions
First Posted Date
2022-10-05
Last Posted Date
2025-07-18
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
5
Registration Number
NCT05567185
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

St Marianna University Hospital, Kanagawa, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Osaka International Cancer Institute, Osaka City, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Toyama University Hospital, Toyama-shi, Japan

and more 1 locations

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Phase 3
Terminated
Conditions
Respiratory Syncytial Virus Prevention
Interventions
Biological: Ad26/protein preF RSV Vaccine
Other: Placebo
First Posted Date
2022-02-16
Last Posted Date
2025-05-23
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
2192
Registration Number
NCT05242432
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Shohokai Toda Internal Medicine and Neurology Clinic, Akashi-shi, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Medical Corporation JR Hiroshima Hospital, Hiroshima-shi, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Seikokai Omi Medical Center, Kusatsu-shi, Japan

and more 27 locations

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
First Posted Date
2021-12-22
Last Posted Date
2025-04-27
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
7
Registration Number
NCT05167825
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Nagano Children's Hospital, Azumino-shi, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Institute of Science Tokyo Hospital, Bunkyo ku, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

Fukuoka Children's Hospital, Fukuoka, Japan

and more 8 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 26
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.